The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.
Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy
Open accessAbstract
BACKGROUND: Venous thromboembolism (VTE) often complicates the clinical course of cancer. The risk is further increased by chemotherapy, but the trade-off between safety and efficacy of primary thromboprophylaxis in cancer patients treated with chemotherapy is uncertain. This is the third update of a review first published in February 2012. OBJECTIVES: To assess the efficacy and safety of primary thromboprophylaxis for VTE in ambulatory cancer patients receiving chemotherapy compared with placebo or no thromboprophylaxis, or an active control intervention. SEARCH METHODS: For this update, the Cochrane Vascular Information Specialist searched the Cochrane Vascular, CENTRAL, MEDLINE, Embase and CINAHL databases and World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 3 August 2020. We also searched the reference lists of identified studies and contacted content experts and trialists for relevant references. SELECTION CRITERIA: Randomised controlled trials comparing any oral or parenteral anticoagulant or mechanical intervention to no thromboprophylaxis or placebo, or comparing two different anticoagulants. DATA COLLECTION AND ANALYSIS: We extracted data on risk of bias, participant characteristics, interventions, and outcomes including symptomatic VTE and major bleeding as the primary effectiveness and safety outcomes, respectively. We applied GRADE to assess the certainty of evidence. MAIN RESULTS: We identified six additional randomised controlled trials (3326 participants) for this update, bringing the included study total to 32 (15,678 participants), all evaluating pharmacological interventions and performed mainly in people with locally advanced or metastatic cancer. The certainty of the evidence ranged from high to very low across the different outcomes and comparisons. The main limiting factors were imprecision and risk of bias. Thromboprophylaxis with direct oral anticoagulants (direct factor Xa inhibitors apixaban and rivaroxaban) may decrease the incidence of symptomatic VTE (risk ratio (RR) 0.43, 95% confidence interval (CI) 0.18 to 1.06; 3 studies, 1526 participants; low-certainty evidence); and probably increases the risk of major bleeding compared with placebo (RR 1.74, 95% CI 0.82 to 3.68; 3 studies, 1494 participants; moderate-certainty evidence). When compared with no thromboprophylaxis, low-molecular-weight heparin (LMWH) reduced the incidence of symptomatic VTE (RR 0.62, 95% CI 0.46 to 0.83; 11 studies, 3931 participants; high-certainty evidence); and probably increased the risk of major bleeding events (RR 1.63, 95% CI 1.12 to 2.35; 15 studies, 7282 participants; moderate-certainty evidence). In participants with multiple myeloma, LMWH resulted in lower symptomatic VTE compared with the vitamin K antagonist warfarin (RR 0.33, 95% CI 0.14 to 0.83; 1 study, 439 participants; high-certainty evidence), while LMWH probably lowers symptomatic VTE more than aspirin (RR 0.51, 95% CI 0.22 to 1.17; 2 studies, 781 participants; moderate-certainty evidence). Major bleeding was observed in none of the participants with multiple myeloma treated with LMWH or warfarin and in less than 1% of those treated with aspirin. Only one study evaluated unfractionated heparin against no thromboprophylaxis, but did not report on VTE or major bleeding. When compared with placebo or no thromboprophylaxis, warfarin may importantly reduce symptomatic VTE (RR 0.15, 95% CI 0.02 to 1.20; 1 study, 311 participants; low-certainty evidence) and may result in a large increase in major bleeding (RR 3.82, 95% CI 0.97 to 15.04; 4 studies, 994 participants; low-certainty evidence). One study evaluated antithrombin versus no antithrombin in children. This study did not report on symptomatic VTE but did report any VTE (symptomatic and incidental VTE). The effect of antithrombin on any VTE and major bleeding is uncertain (any VTE: RR 0.84, 95% CI 0.41 to 1.73; major bleeding: RR 0.78, 95% CI 0.03 to 18.57; 1 study, 85 participants; very low-certainty evidence). AUTHORS' CONCLUSIONS: In ambulatory cancer patients, primary thromboprophylaxis with direct factor Xa inhibitors may reduce the incidence of symptomatic VTE (low-certainty evidence) and probably increases the risk of major bleeding (moderate-certainty evidence) when compared with placebo. LMWH decreases the incidence of symptomatic VTE (high-certainty evidence), but increases the risk of major bleeding (moderate-certainty evidence) when compared with placebo or no thromboprophylaxis. Evidence for the use of thromboprophylaxis with anticoagulants other than direct factor Xa inhibitors and LMWH is limited. More studies are warranted to evaluate the efficacy and safety of primary prophylaxis in specific types of chemotherapeutic agents and types of cancer, such as gastrointestinal or genitourinary cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration
Higgins, J. P. T., Green, S. R., & Higgins, J. P. T. (2008) · Cited by 7,175
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., & KEARON, C. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01204.x · Cited by 5,009
Funnel plots for detecting bias in meta-analysis
Sterne, J. A. C., & Egger, M. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00377-8 · Cited by 3,779
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Kahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
A modified test for small‐study effects in meta‐analyses of controlled trials with binary endpoints
Harbord, R. M., Egger, M., & Sterne, J. A. C. (2006) · Statistics in Medicine · doi:10.1002/sim.2380 · Cited by 2,267
Development and validation of a predictive model for chemotherapy-associated thrombosis
Khorana, A. A., Kuderer, N. M., Culakova, E., Lyman, G. H., & Francis, C. W. (2008) · Blood · doi:10.1182/blood-2007-10-116327 · Cited by 2,217
Prandoni, P., Lensing, A. W. A., Piccioli, A., Bernardi, E., Simioni, P., Girolami, B., Marchiori, A., Sabbion, P., Prins, M. H., Noventa, F., et al. (2002) · Blood · doi:10.1182/blood-2002-01-0108 · Cited by 1,863
Bayesian Approaches to Clinical Trials and Health‐Care Evaluation
Spiegelhalter, D. J., Abrams, K. R., & Myles, J. P. (2003) · Wiley eBooks · doi:10.1002/0470092602 · Cited by 1,673
Prognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Kaatz, S., Ahmad, D., Spyropoulos, A. C., & Schulman, S. (2015) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13140 · Cited by 1,419
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Undue reliance on I 2 in assessing heterogeneity may mislead
Rücker, G., Schwarzer, G., Carpenter, J. R., & Schumacher, M. (2008) · BMC Medical Research Methodology · doi:10.1186/1471-2288-8-79 · Cited by 1,287
Epidemiology of venous thromboembolism
Heit, J. A. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.83 · Cited by 1,277
Epidemiology of cancer-associated venous thrombosis
Timp, J. F., Braekkan, S. K., Versteeg, H. H., & Cannegieter, S. C. (2013) · Blood · doi:10.1182/blood-2013-04-460121 · Cited by 1,205
Lyman, G. H., Khorana, A. A., Falanga, A., Clarke-Pearson, D., Flowers, C., Jahanzeb, M., Kakkar, A., Kuderer, N. M., Levine, M. N., Liebman, H., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.1283 · Cited by 952
Prediction of venous thromboembolism in cancer patients
Ay, C., Dunkler, D., Marosi, C., Chiriac, A.-L., Vormittag, R., Simanek, R., Quehenberger, P., Zielinski, C., & Pabinger, I. (2010) · Blood · doi:10.1182/blood-2010-02-270116 · Cited by 772
Hutten, B. A., Prins, M. H., Gent, M., Ginsberg, J., Tijssen, J. G. P., & Büller, H. R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3078 · Cited by 748
Viscosupplementation for Osteoarthritis of the Knee: A Systematic Review and Meta-analysis
Rutjes, A. W. S., Jüni, P., da Costa, B. R., Trelle, S., Nüesch, E., & Reichenbach, S. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-3-201208070-00473 · Cited by 717
Self-citationLyman, G. H., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., Gates, L. E., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.1118 · Cited by 713
Kakkar, A. K., Levine, M. N., Kadziola, Z., Lemoine, N. R., Low, V., Patel, H. K., Rustin, G., Thomas, M., Quigley, M., & Williamson, R. C. N. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.002 · Cited by 650
Agnelli, G., Gussoni, G., Bianchini, C., Verso, M., Mandalà, M., Cavanna, L., Barni, S., Labianca, R., Buzzi, F., Scambia, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70232-3 · Cited by 598
The Effect of Low Molecular Weight Heparin on Survival in Patients With Advanced Malignancy
Klerk, C. P. W., Smorenburg, S. M., Otten, H.-M., Lensing, A. W. A., Prins, M. H., Piovella, F., Prandoni, P., Bos, M. M. E. M., Richel, D. J., van Tienhoven, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.134 · Cited by 596
Self-citationRisk of Venous Thromboembolism in Patients with Cancer: A Systematic Review and Meta-Analysis
Horsted, F., West, J., & Grainge, M. J. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001275 · Cited by 565
Assessing Risk of Venous Thromboembolism in the Patient With Cancer
Khorana, A. A., & Connolly, G. C. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3271 · Cited by 539
Semuloparin for Thromboprophylaxis in Patients Receiving Chemotherapy for Cancer
Agnelli, G., George, D. J., Kakkar, A. K., Fisher, W., Lassen, M. R., Mismetti, P., Mouret, P., Chaudhari, U., Lawson, F., & Turpie, A. G. G. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1108898 · Cited by 531
Weitz, J. I., Eikelboom, J. W., & Samama, M. M. (2012) · Chest · doi:10.1378/chest.11-2294 · Cited by 527
Levine, M., Hirsh, J., Arnold, A., Gent, M., Levine, M., Arnold, A., Bramwell, V., Pritchard, K. I., Stewart, D., Warr, D., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90008-6 · Cited by 510
Cancer-associated venous thromboembolism: Burden, mechanisms, and management
Ay, C., Pabinger, I., & Cohen, A. T. (2017) · Thrombosis and Haemostasis · doi:10.1160/th16-08-0615 · Cited by 496
Altinbas, M., Coskun, H. S., Er, O., Ozkan, M., Eser, B., Unal, A., Cetin, M., & Soyuer, S. (2004) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2004.00871.x · Cited by 455
Zacharski, L. R., Henderson, W. G., Rickles, F. R., Forman, W. B., Cornell, C. J., Forcier, A. J., Edwards, R. L., Headley, E., Kim, S.-H., O'Donnell, J. F., et al. (1984) · Cancer · doi:10.1002/1097-0142(19840515)53:10<2046::aid-cncr2820531007>3.0.co;2-f · Cited by 343
Palumbo, A., Cavo, M., Bringhen, S., Zamagni, E., Romano, A., Patriarca, F., Rossi, D., Gentilini, F., Crippa, C., Galli, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.6844 · Cited by 323
Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer
Maraveyas, A., Waters, J., Roy, R., Fyfe, D., Propper, D., Lofts, F., Sgouros, J., Gardiner, E., Wedgwood, K., Ettelaie, C., et al. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.10.017 · Cited by 316
Combining the Antidepressant Drugs
(1965) · The Lancet · doi:10.1016/s0140-6736(65)92230-0 · Cited by 299
Katholing, A., Rietbrock, S., Bamber, L., Martinez, C., & Cohen, A. T. (2017) · Thrombosis and Haemostasis · doi:10.1160/th15-08-0686 · Cited by 294
Larocca, A., Cavallo, F., Bringhen, S., Di Raimondo, F., Falanga, A., Evangelista, A., Cavalli, M., Stanevsky, A., Corradini, P., Pezzatti, S., et al. (2012) · Blood · doi:10.1182/blood-2011-03-344333 · Cited by 288
Subcutaneous heparin treatment increases survival in small cell lung cancer
Lebeau, B., Chastang, C., Brechot, J.-M., Capron, F., Dautzenberg, B., Delaisements, C., Mornet, M., Brun, J., Hurdebourcq, J.-P., & Lemarie, E. (1994) · Cancer · doi:10.1002/1097-0142(19940701)74:1<38::aid-cncr2820740108>3.0.co;2-e · Cited by 277
Transcutaneous electrostimulation for osteoarthritis of the knee
Rutjes, A. W., Nüesch, E., Sterchi, R., Kalichman, L., Hendriks, E., Osiri, M., Brosseau, L., Reichenbach, S., & Jüni, P. (2009) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002823.pub2 · Cited by 272
Self-citationPelzer, U., Opitz, B., Deutschinoff, G., Stauch, M., Reitzig, P. C., Hahnfeld, S., Müller, L., Grunewald, M., Stieler, J. M., Sinn, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.1481 · Cited by 268
PERRY, J. R., JULIAN, J. A., LAPERRIERE, N. J., GEERTS, W., AGNELLI, G., ROGERS, L. R., MALKIN, M. G., SAWAYA, R., BAKER, R., FALANGA, A., et al. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03973.x · Cited by 249
Baz, R., Li, L., Kottke-Marchant, K., Srkalovic, G., McGowan, B., Yiannaki, E., Karam, M. A., Faiman, B., Jawde, R. A., Andresen, S., et al. (2005) · Mayo Clinic Proceedings · doi:10.4065/80.12.1568 · Cited by 228
Zacharski, L. R. (1981) · JAMA · doi:10.1001/jama.245.8.831 · Cited by 206
Chahinian, A. P., Propert, K. J., Ware, J. H., Zimmer, B., Perry, M. C., Hirsh, V, Skarin, A., Kopel, S., Holland, J. F., & Comis, R. L. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.8.993 · Cited by 193
LEVINE, M. N., GU, C., LIEBMAN, H. A., ESCALANTE, C. P., SOLYMOSS, S., DEITCHMAN, D., RAMIREZ, L., & JULIAN, J. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2012.04693.x · Cited by 190
Haas, S. K., Freund, M., Heigener, D., Heilmann, L., Kemkes-Matthes, B., Tempelhoff, G.-F. V., Melzer, N., & Kakkar, A. K. (2012) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029611433769 · Cited by 180
Macbeth, F., Noble, S., Evans, J., Ahmed, S., Cohen, D., Hood, K., Knoyle, D., Linnane, S., Longo, M., Moore, B., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0268 · Cited by 178
Low-Molecular-Weight Heparin in Patients With Advanced Cancer: A Phase 3 Clinical Trial
Sideras, K., Schaefer, P. L., Okuno, S. H., Sloan, J. A., Kutteh, L., Fitch, T. R., Dakhil, S. R., Levitt, R., Alberts, S. R., Morton, R. F., et al. (2006) · Mayo Clinic Proceedings · doi:10.4065/81.6.758 · Cited by 163
Khorana, A. A., Streiff, M. B., Farge, D., Mandala, M., Debourdeau, P., Cajfinger, F., Marty, M., Falanga, A., & Lyman, G. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3214 · Cited by 162
Donato, J., Campigotto, F., Uhlmann, E. J., Coletti, E., Neuberg, D. S., Weber, G. M., & Zwicker, J. I. (2015) · Blood · doi:10.1182/blood-2015-02-626788 · Cited by 160
Zwicker, J. I., Liebman, H. A., Bauer, K. A., Caughey, T., Campigotto, F., Rosovsky, R. P. G., Mantha, S. H., Kessler, C. M., Eneman, J. D., Raghavan, V. R., et al. (2012) · British Journal of Haematology · doi:10.1111/bjh.12163 · Cited by 142
Andrew, M. E., Hanna, K., Abshire, T. C., et al. (2003) · Thrombosis and Haemostasis · doi:10.1160/th02-11-0283 · Cited by 141
Maurer, L. H., Herndon, J. E., Hollis, D. R., Aisner, J., Carey, R. W., Skarin, A. T., Perry, M. C., Eaton, W. L., Zacharski, L., Hammond, S., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.11.3378 · Cited by 123
Barni, S., Labianca, R., Agnelli, G., Bonizzoni, E., Verso, M., Mandalà, M., Brighenti, M., Petrelli, F., Bianchini, C., Perrone, T., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-179 · Cited by 102
Bleeding complications during anticoagulant treatment in patients with cancer
Kamphuisen, P. W., & Beyer‐Westendorf, J. (2014) · Thrombosis Research · doi:10.1016/s0049-3848(14)50009-6 · Cited by 95
Anticoagulation for patients with cancer and central venous catheters
Akl, E. A., Vasireddi, S. R., Gunukula, S. K., Yosuico, V. E. D., Barba, M., Sperati, F., Cook, D., & Schünemann, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006468.pub3 · Cited by 85
Riess, H. B., Pelzer, U., Hilbig, A., Stieler, J., Opitz, B., Scholten, T., Kauschat-Brüning, D., Bramlage, P., Dörken, B., & Oettle, H. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-361 · Cited by 81
Rieß, H., Pelzer, U., Opitz, B., Stauch, M. B., Reitzig, P., Hahnfeld, S., Müller, L., Stieler, J., Dörken, B., & Oettle, H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.15_suppl.4033 · Cited by 76
Khorana, A. A., Vadhan‐Raj, S., Kuderer, N. M., Wun, T., Liebman, H. A., Soff, G. A., Belani, C. P., O'Reilly, E. M., McBane, R. D., Eikelboom, J. W., et al. (2017) · Thrombosis and Haemostasis · doi:10.1160/th17-03-0171 · Cited by 67
Verso, M., Gussoni, G., & Agnelli, G. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.03901.x · Cited by 64
Niesvizky, R., Martinez-Banos, D. M., Jalbrzikowski, J., Christos, P. J., Furst, J. R., Sancho, M. D., Mark, T. M., Pearse, R. N., Mazumdar, M., Zafar, F., et al. (2007) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190701647887 · Cited by 61
Griffiths, G. O., Burns, S., Noble, S., Macbeth, F. R., Cohen, D. R., & Maughan, T. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-355 · Cited by 61
Prophylaxis against Venous Thromboembolism in Ambulatory Patients with Cancer
Connors, J. M. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1401468 · Cited by 61
Palumbo, A., Rus, C. P., Zeldis, J. B., Rodeghiero, F., & Boccadoro, M. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2006.02059.x · Cited by 44
Perry, J., Rogers, L., Laperrière, N., Julian, J. A., Geerts, W. H., Agnelli, G., Malkin, M. G., Sawaya, R., Baker, R. I., & Levine, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.2011 · Cited by 42
Rajan, R., Gafni, A., Levine, M. N., Hirsh, J., & Gent, M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.42 · Cited by 40
Anticoagulation for patients with cancer and central venous catheters
Akl, E. A., Vasireddi, S. R., Gunukula, S. K., Yosuico, V. E. D., Barba, M., Sperati, F., Cook, D., & Schünemann, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006468.pub4 · Cited by 35
Bennett, C. L., & Maxwell, W. D. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1328893 · Cited by 31
Palumbo, A., Cavo, M., Bringhen, S., Cavalli, M. M., Patriarca, F. F., Rossi, D., Tacchetti, P., Pescosta, N., Crippa, C., Galli, M., et al. (2009) · Blood · doi:10.1182/blood.v114.22.492.492 · Cited by 21
Bocharov, A. V., Григорьевич, Ч. В., Ukhanov, A. P., & Vi, C. (2011) · PubMed · Cited by 5
Explaining heterogeneity in meta-analysis: a comparison of methods
Thompson, S. G., & Sharp, S. J. (1999) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19991030)18:20
Cited by
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Epidemiology of cancer-associated venous thrombosis
Timp, J. F., Braekkan, S. K., Versteeg, H. H., & Cannegieter, S. C. (2013) · Blood · doi:10.1182/blood-2013-04-460121 · Cited by 1,205
Lyman, G. H., Carrier, M., Ay, C., Di Nisio, M., Hicks, L. K., Khorana, A. A., Leavitt, A. D., Lee, A. Y. Y., Macbeth, F., Morgan, R. L., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020003442 · Cited by 893
Self-citationApixaban to Prevent Venous Thromboembolism in Patients with Cancer
Carrier, M., Abou-Nassar, K., Mallick, R., Tagalakis, V., Shivakumar, S., Schattner, A., Kuruvilla, P., Hill, D., Spadafora, S., Marquis, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814468 · Cited by 852
Metadata
- Authors
- Di Nisio, M., Porreca, E., Ferrante, N., Otten, H.-M., Cuccurullo, F., & Rutjes, A. W.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- John Wiley & Sons, Ltd
- Published
- 2012-02-15
- Volume
- 12
- Issue
- 2
- Pages
- CD008500-CD008500
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2116435978
- Cited by
- 264
- References
- 77
- Type
- reference entry
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.